礼来公司 （Eli Lilly） 的盈利超出预期，上调了 2025 年的前景，投资者购买量增加。 Eli Lilly beat earnings estimates, raised 2025 outlook, and saw increased investor buying.

Elilly报告Q2收入丰厚,其收入为6.31 EPS和15.56亿美元,超过估计数,并将2025年EPS指南提高到21.75-23.00美元。 Eli Lilly reported strong Q2 earnings with $6.31 EPS and $15.56 billion in revenue, surpassing estimates, and raised its 2025 EPS guidance to $21.75–23.00. 机构投资者,包括Phillips财务管理公司和Cookson Peirce公司增加了股份,内部投资者购买了280多万美元的股份。 Institutional investors increased holdings, including Phillips Financial Management and Cookson Peirce, while insiders bought over $2.8 million in shares. 股票交易额为799.85美元,市场上限为7 570亿美元,协商一致的“Moderate Buy”评级为938.61美元,目标是938.61美元。 The stock, trading at $799.85, has a market cap of $757 billion and a consensus "Moderate Buy" rating with a $938.61 target.